Effects of 5:2 intermittent fasting meal replacement on body composition and abdominal fat distribution in overweight and obese adults with early type 2 diabetes
Abstract
BACKGROUND AND AIMS
The 5:2 intermittent fasting meal replacement (5:2 MR) improved glycemic control and weight loss in adults with type 2 diabetes mellitus (T2DM).
OBJECTIVE
This analysis further investigated the exploratory outcomes related to body composition and abdominal fat distribution.
METHODS
This was a single-center analysis of a randomized, active-controlled trial (EARLY), which enrolled overweight and obese patients with early T2DM. A total of 85 participants were randomly assigned to receive metformin (n = 28), empagliflozin (n = 28), or 5:2 MR (n = 29) for 16 weeks. Body composition was assessed using InBody device, and the energy spectrum CT was used to measure abdominal fat distribution. Spearman's correlation coefficient was used to evaluate the associations between change in body mass index (BMI) and change in the exploratory outcomes.
RESULTS
Compared with the metformin and empagliflozin groups, the 5:2 MR group showed the most significant reductions in BMI (least-squares mean, -3.41 kg/m2 [standard error, 0.31], P < 0.001), waist circumference (-8.83 cm [1.07], P < 0.001), waist-to-hip ratio (WHR) (-0.04 [0.01], P < 0.05), waist-to-height ratio (WHtR) (-0.05 [0.01], P < 0.001), body fat percentage (BF%) (-4.84 % [0.66], P < 0.05), abdominal cross-sectional area (ACSA) (-66.05 cm2 [9.46], P < 0.01), subcutaneous fat area (-58.27 cm2 [5.99], P < 0.001), and an increase in the liver-to-spleen (L/S) ratio) (0.43 [0.04], P < 0.01). In the 5:2 MR group, changes…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 85 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.